154 related articles for article (PubMed ID: 2190554)
21. Specificity of retroviral proteases: an analysis of viral and nonviral protein substrates.
Tomasselli AG; Heinrikson RL
Methods Enzymol; 1994; 241():279-301. PubMed ID: 7854182
[No Abstract] [Full Text] [Related]
22. 15gag proteinase of myeloblastosis-associated virus: specificity studies with substrate-based inhibitors.
Pavlícková L; Stys D; Soucek M; Urban J; Hrusková O; Sedlácek J; Strop P
Arch Biochem Biophys; 1992 Nov; 298(2):753-6. PubMed ID: 1417001
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors.
Dreyer GB; Metcalf BW; Tomaszek TA; Carr TJ; Chandler AC; Hyland L; Fakhoury SA; Magaard VW; Moore ML; Strickler JE
Proc Natl Acad Sci U S A; 1989 Dec; 86(24):9752-6. PubMed ID: 2690072
[TBL] [Abstract][Full Text] [Related]
24. Modulation of the affinity of aspartic proteases by the mutated residues in active site models.
Goldblum A
FEBS Lett; 1990 Feb; 261(2):241-4. PubMed ID: 2107098
[TBL] [Abstract][Full Text] [Related]
25. Recombinant HIV2 protease processes HIV1 Pr53gag and analogous junction peptides in vitro.
Pichuantes S; Babé LM; Barr PJ; DeCamp DL; Craik CS
J Biol Chem; 1990 Aug; 265(23):13890-8. PubMed ID: 2199446
[TBL] [Abstract][Full Text] [Related]
26. Peptide substrates and inhibitors of the HIV-1 protease.
Moore ML; Bryan WM; Fakhoury SA; Magaard VW; Huffman WF; Dayton BD; Meek TD; Hyland L; Dreyer GB; Metcalf BW
Biochem Biophys Res Commun; 1989 Mar; 159(2):420-5. PubMed ID: 2649094
[TBL] [Abstract][Full Text] [Related]
27. Molecular dynamics simulations of HIV-1 protease with peptide substrate.
Harrison RW; Weber IT
Protein Eng; 1994 Nov; 7(11):1353-63. PubMed ID: 7700867
[TBL] [Abstract][Full Text] [Related]
28. Effect of substrate residues on the P2' preference of retroviral proteinases.
Boross P; Bagossi P; Copeland TD; Oroszlan S; Louis JM; Tözsér J
Eur J Biochem; 1999 Sep; 264(3):921-9. PubMed ID: 10491141
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins.
Tözsér J; Bláha I; Copeland TD; Wondrak EM; Oroszlan S
FEBS Lett; 1991 Apr; 281(1-2):77-80. PubMed ID: 2015912
[TBL] [Abstract][Full Text] [Related]
30. Kinetic and modeling studies of subsites S4-S3' of Moloney murine leukemia virus protease.
Menéndez-Arias L; Weber IT; Soss J; Harrison RW; Gotte D; Oroszlan S
J Biol Chem; 1994 Jun; 269(24):16795-801. PubMed ID: 8207003
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of porcine pepsin by two substrate analogues containing statine. The effect of histidine at the P2 subsite on the inhibition of aspartic proteinases.
Maibaum J; Rich DH
J Med Chem; 1988 Mar; 31(3):625-9. PubMed ID: 3126296
[TBL] [Abstract][Full Text] [Related]
32. Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein.
Shoeman RL; Höner B; Stoller TJ; Kesselmeier C; Miedel MC; Traub P; Graves MC
Proc Natl Acad Sci U S A; 1990 Aug; 87(16):6336-40. PubMed ID: 2201025
[TBL] [Abstract][Full Text] [Related]
33. Separation and partial characterization of proteinases with substrate specificity for basic amino acids from human MOLT-4 T lymphocytes: identification of those inhibited by variable-loop-V3 peptides of HIV-1 (human immunodeficiency virus-1) envelope glycoprotein.
Harvima IT; Harvima RJ; Nilsson G; Ivanoff L; Schwartz LB
Biochem J; 1993 Jun; 292 ( Pt 3)(Pt 3):711-8. PubMed ID: 8318003
[TBL] [Abstract][Full Text] [Related]
34. Studies of human immunodeficiency virus type 1 (HIV-1) protease inhibitors. III. Structure-activity relationship of HIV-1 protease inhibitors containing cyclohexylalanylalanine hydroxyethylene dipeptide isostere.
Sakurai M; Higashida S; Sugano M; Handa H; Komai T; Yagi R; Nishigaki T; Yabe Y
Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):534-40. PubMed ID: 8004698
[TBL] [Abstract][Full Text] [Related]
35. Molecular basis for the relative substrate specificity of human immunodeficiency virus type 1 and feline immunodeficiency virus proteases.
Beck ZQ; Lin YC; Elder JH
J Virol; 2001 Oct; 75(19):9458-69. PubMed ID: 11533208
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of "norpeptides" as potential inhibitors of HIV-proteases.
Burgess K; Pal B
Bioorg Med Chem; 1994 Jan; 2(1):23-6. PubMed ID: 7922117
[TBL] [Abstract][Full Text] [Related]
37. Identification of a human immunodeficiency virus-1 protease cleavage site within the 66,000 Dalton subunit of reverse transcriptase.
Graves MC; Meidel MC; Pan YC; Manneberg M; Lahm HW; Grüninger-Leitch F
Biochem Biophys Res Commun; 1990 Apr; 168(1):30-6. PubMed ID: 1691640
[TBL] [Abstract][Full Text] [Related]
38. Chromophoric peptide substrates for the spectrophotometric assay of HIV-1 protease.
Tomaszek TA; Magaard VW; Bryan HG; Moore ML; Meek TD
Biochem Biophys Res Commun; 1990 Apr; 168(1):274-80. PubMed ID: 2183799
[TBL] [Abstract][Full Text] [Related]
39. Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites.
Bagossi P; Sperka T; Fehér A; Kádas J; Zahuczky G; Miklóssy G; Boross P; Tözsér J
J Virol; 2005 Apr; 79(7):4213-8. PubMed ID: 15767422
[TBL] [Abstract][Full Text] [Related]
40. HIV protease (HIV PR) inhibitor structure-activity-selectivity, and active site molecular modeling of high affinity Leu [CH(OH)CH2]Val modified viral and nonviral substrate analogs.
Sawyer TK; Staples DJ; Liu L; Tomasselli AG; Hui JO; O'Connell K; Schostarez H; Hester JB; Moon J; Howe WJ
Int J Pept Protein Res; 1992; 40(3-4):274-81. PubMed ID: 1478785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
